SO SAD ANOTHER CANDAIAN PHARMA COMPANY GOES DOWN THE DRAINLooking at the conference call, it seems like the north american sector of the company is just hemorrhaging and really underperforming. This is only the asset that matters cause they still owe some money on the international secment which actually is holding up quite well (excluding foreign exchange).
I am curious to see what the new CEO does here. I have seen companies with bonds trading around these levels in far far far worst shape and bounce back. However, that being said don't be stupid and be cautious.
All the best